CL2012003039A1 - Polietilenglicol conjugado a factor viii mediante un grupo conector; composicion farmaceutica que comprende dicho polietilenglicol conjugado; uso de dicha composicion para tratamiento de una enfermedad o trauma de la coagulacion de la sangre. - Google Patents
Polietilenglicol conjugado a factor viii mediante un grupo conector; composicion farmaceutica que comprende dicho polietilenglicol conjugado; uso de dicha composicion para tratamiento de una enfermedad o trauma de la coagulacion de la sangre.Info
- Publication number
- CL2012003039A1 CL2012003039A1 CL2012003039A CL2012003039A CL2012003039A1 CL 2012003039 A1 CL2012003039 A1 CL 2012003039A1 CL 2012003039 A CL2012003039 A CL 2012003039A CL 2012003039 A CL2012003039 A CL 2012003039A CL 2012003039 A1 CL2012003039 A1 CL 2012003039A1
- Authority
- CL
- Chile
- Prior art keywords
- polyethylene glycol
- conjugated
- composition
- trauma
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1007357.5A GB201007357D0 (en) | 2010-04-30 | 2010-04-30 | Conjugated factor VIII |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012003039A1 true CL2012003039A1 (es) | 2014-01-24 |
Family
ID=42289987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012003039A CL2012003039A1 (es) | 2010-04-30 | 2012-10-29 | Polietilenglicol conjugado a factor viii mediante un grupo conector; composicion farmaceutica que comprende dicho polietilenglicol conjugado; uso de dicha composicion para tratamiento de una enfermedad o trauma de la coagulacion de la sangre. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20130150302A1 (es) |
| EP (1) | EP2563402A1 (es) |
| JP (1) | JP5870088B2 (es) |
| KR (1) | KR20130055619A (es) |
| CN (1) | CN102939108A (es) |
| AP (1) | AP2012006575A0 (es) |
| AU (1) | AU2011247147B2 (es) |
| BR (1) | BR112012027590A2 (es) |
| CA (1) | CA2797058A1 (es) |
| CL (1) | CL2012003039A1 (es) |
| CO (1) | CO6660443A2 (es) |
| CR (1) | CR20120579A (es) |
| EA (1) | EA201290938A1 (es) |
| EC (1) | ECSP12012314A (es) |
| GB (2) | GB201007357D0 (es) |
| HK (1) | HK1173946A1 (es) |
| IL (1) | IL222566A (es) |
| MX (1) | MX2012012683A (es) |
| MY (1) | MY160922A (es) |
| NI (1) | NI201200160A (es) |
| NZ (1) | NZ603939A (es) |
| PE (1) | PE20130254A1 (es) |
| RU (1) | RU2012144555A (es) |
| SG (1) | SG184906A1 (es) |
| WO (1) | WO2011135307A1 (es) |
| ZA (1) | ZA201208989B (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11351112B2 (en) | 2012-04-16 | 2022-06-07 | Cantab Biopharmaceuticals Patents Limited | Optimised subcutaneous therapeutic agents |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2670618C (en) | 2006-12-15 | 2016-10-04 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
| KR101912335B1 (ko) | 2009-07-27 | 2018-10-26 | 리폭센 테크놀로지즈 리미티드 | 비혈액 응고 단백질의 글리코폴리시알화 |
| ES2597954T3 (es) | 2009-07-27 | 2017-01-24 | Baxalta GmbH | Conjugados de proteína de la coagulación sanguínea |
| NZ623810A (en) | 2009-07-27 | 2015-10-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| BR112013015898A2 (pt) | 2010-12-22 | 2018-06-26 | Baxter International Inc. | derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada. |
| GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
| GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
| GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
| KR20190086269A (ko) * | 2018-01-12 | 2019-07-22 | 재단법인 목암생명과학연구소 | 체내 지속형 재조합 당단백질 및 이의 제조방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE058897T2 (hu) * | 2003-02-26 | 2022-09-28 | Nektar Therapeutics | Polimer VIII-as faktor egység konjugátumok |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| EP1824988B1 (en) * | 2004-11-12 | 2017-04-19 | Bayer HealthCare LLC | Site-directed modification of fviii |
| CN101163506B (zh) * | 2004-12-27 | 2012-09-26 | 巴克斯特国际公司 | 聚合物-von Willebrand因子偶联物 |
| BRPI0708832A2 (pt) * | 2006-03-31 | 2011-06-14 | Baxter Int | construÇço proteinÁcea |
| ES2597849T3 (es) | 2007-10-09 | 2017-01-23 | Polytherics Limited | Proteínas y péptidos conjugados novedosos |
| MX2010011672A (es) | 2008-04-24 | 2011-03-02 | Celtic Pharma Peg Ltd | Conjugados del factor ix con vidas medias extendidas. |
| KR101763559B1 (ko) * | 2008-07-21 | 2017-08-14 | 폴리테릭스 리미티드 | 생물학적 분자의 컨쥬게이팅을 위한 신규한 시약 및 방법 |
| GB0912485D0 (en) * | 2009-07-17 | 2009-08-26 | Polytherics Ltd | Improved conjugation method |
-
2010
- 2010-04-30 GB GBGB1007357.5A patent/GB201007357D0/en not_active Ceased
-
2011
- 2011-04-28 PE PE2012002104A patent/PE20130254A1/es not_active Application Discontinuation
- 2011-04-28 NZ NZ603939A patent/NZ603939A/xx not_active IP Right Cessation
- 2011-04-28 JP JP2013506735A patent/JP5870088B2/ja not_active Expired - Fee Related
- 2011-04-28 RU RU2012144555/15A patent/RU2012144555A/ru not_active Application Discontinuation
- 2011-04-28 MX MX2012012683A patent/MX2012012683A/es not_active Application Discontinuation
- 2011-04-28 EP EP11719040A patent/EP2563402A1/en not_active Withdrawn
- 2011-04-28 SG SG2012077087A patent/SG184906A1/en unknown
- 2011-04-28 KR KR1020127031386A patent/KR20130055619A/ko not_active Application Discontinuation
- 2011-04-28 GB GB201220667A patent/GB2492935B8/en not_active Expired - Fee Related
- 2011-04-28 AU AU2011247147A patent/AU2011247147B2/en not_active Ceased
- 2011-04-28 BR BR112012027590A patent/BR112012027590A2/pt not_active IP Right Cessation
- 2011-04-28 AP AP2012006575A patent/AP2012006575A0/xx unknown
- 2011-04-28 CA CA2797058A patent/CA2797058A1/en active Pending
- 2011-04-28 WO PCT/GB2011/000662 patent/WO2011135307A1/en active Application Filing
- 2011-04-28 US US13/643,287 patent/US20130150302A1/en not_active Abandoned
- 2011-04-28 MY MYPI2012004710A patent/MY160922A/en unknown
- 2011-04-28 EA EA201290938A patent/EA201290938A1/ru unknown
- 2011-04-28 CN CN2011800218881A patent/CN102939108A/zh active Pending
-
2012
- 2012-10-21 IL IL222566A patent/IL222566A/en not_active IP Right Cessation
- 2012-10-29 CL CL2012003039A patent/CL2012003039A1/es unknown
- 2012-10-29 NI NI201200160A patent/NI201200160A/es unknown
- 2012-11-14 CR CR20120579A patent/CR20120579A/es unknown
- 2012-11-28 EC ECSP12012314 patent/ECSP12012314A/es unknown
- 2012-11-28 ZA ZA2012/08989A patent/ZA201208989B/en unknown
- 2012-11-29 CO CO12216949A patent/CO6660443A2/es unknown
-
2013
- 2013-01-18 HK HK13100809.6A patent/HK1173946A1/xx not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11351112B2 (en) | 2012-04-16 | 2022-06-07 | Cantab Biopharmaceuticals Patents Limited | Optimised subcutaneous therapeutic agents |
Also Published As
| Publication number | Publication date |
|---|---|
| PE20130254A1 (es) | 2013-03-16 |
| HK1173946A1 (en) | 2013-05-31 |
| BR112012027590A2 (pt) | 2016-08-09 |
| SG184906A1 (en) | 2012-11-29 |
| WO2011135307A1 (en) | 2011-11-03 |
| NZ603939A (en) | 2013-08-30 |
| KR20130055619A (ko) | 2013-05-28 |
| GB2492935B8 (en) | 2014-10-29 |
| EA201290938A1 (ru) | 2013-04-30 |
| IL222566A (en) | 2017-12-31 |
| MY160922A (en) | 2017-03-31 |
| ZA201208989B (en) | 2014-02-26 |
| CR20120579A (es) | 2013-04-25 |
| AP2012006575A0 (en) | 2012-12-31 |
| GB2492935A (en) | 2013-01-16 |
| MX2012012683A (es) | 2013-04-03 |
| EP2563402A1 (en) | 2013-03-06 |
| GB2492935A8 (en) | 2014-10-29 |
| CN102939108A (zh) | 2013-02-20 |
| IL222566A0 (en) | 2012-12-31 |
| JP2013525414A (ja) | 2013-06-20 |
| AU2011247147B2 (en) | 2014-09-18 |
| GB2492935B (en) | 2014-04-30 |
| ECSP12012314A (es) | 2013-05-31 |
| NI201200160A (es) | 2013-04-19 |
| AU2011247147A1 (en) | 2013-01-10 |
| GB201007357D0 (en) | 2010-06-16 |
| US20130150302A1 (en) | 2013-06-13 |
| CA2797058A1 (en) | 2011-11-03 |
| CO6660443A2 (es) | 2013-04-30 |
| RU2012144555A (ru) | 2014-06-10 |
| GB201220667D0 (en) | 2013-01-02 |
| JP5870088B2 (ja) | 2016-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012003039A1 (es) | Polietilenglicol conjugado a factor viii mediante un grupo conector; composicion farmaceutica que comprende dicho polietilenglicol conjugado; uso de dicha composicion para tratamiento de una enfermedad o trauma de la coagulacion de la sangre. | |
| CL2012003038A1 (es) | Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia. | |
| BRPI1012116A2 (pt) | composição farmacêutica para o tratamento de doenças cardíacas | |
| CR20150625A (es) | Composición que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas | |
| CL2013000801A1 (es) | Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion | |
| BRPI0910557A2 (pt) | composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso. | |
| BRPI1009324A2 (pt) | compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos | |
| BR112013007577A2 (pt) | conjugado, composição farmacêutica, molécula de conjugação com amatoxina e método para a síntese de um conjugado | |
| BR112014016165A8 (pt) | compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido | |
| BR112013023174A2 (pt) | "compostos derivados de triterpenoide de c4-monometila, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos" | |
| BRPI1012276A2 (pt) | "dispositivo para distribuir medicamento líquido." | |
| CL2011002943A1 (es) | Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica. | |
| BRPI1006040A2 (pt) | uso de composições farmacêuticas, tipo de curativo médico, e, tipo de caixa de medicamento | |
| IT1400982B1 (it) | Collirio osmotico trans-epiteliale per la cura del cheratocono. | |
| BRPI0815613A2 (pt) | Composições lipossômicas para administração in vivo de compostos de ácido borônico. | |
| ECSP13012467A (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
| DK2254549T3 (da) | Vandige farmaceutiske sammensætninger, indeholdende borat-polyol-komplekser | |
| BRPI1006024B8 (pt) | composição cosmética emulsificada para cuidado da pele | |
| BRPI1009392A2 (pt) | "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica." | |
| BRPI0907228A2 (pt) | Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos | |
| CL2013000734A1 (es) | Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico. | |
| BRPI0909101A2 (pt) | Adesivos medicinais para cirurgia compreendendo compostos bioativos | |
| FR2961682B1 (fr) | Instrument chirurgical notamment pour chirurgie peritoneale | |
| CL2011002265A1 (es) | Composicion farmaceutica que comprende simvastatina, enalapril y acido acetilsalicilico; uso para prevenir y tratar enfermedades cardiovasculares. | |
| PE20151603A1 (es) | Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos |